3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hematologic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Mature B-cell Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, B-Cell
1
Interventions
Cyclophosphamide
5
ibrutinib
4
fludarabine
4
pirtobrutinib
3
obinutuzumab
3
acalabrutinib
3
fludarabine phosphate
2
Rituximab
2
Mesna
2
venetoclax
1
ricolinostat
1
idelalisib
1
Whole-Body Irradiation
1
Vincristine
1
Tacrolimus
1
Stem Cell Transplantation
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Melphalan
1
Leukapheresis
1
Doxorubicin
1
Diet
1
Busulfan
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
ARQ531
×
90 days
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled